Trillium Reports 2015 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Leerink Partners Remains Bullish as Trillium Therapeutics (TRIL) Continues TTI-621 Development
March 10, 2016 7:48 AM ESTLeerink Partners maintained an Outperform rating on Trillium Therapeutics (NASDAQ: TRIL) price target of $20.00 (from $29.00). Earlier this year TRIL initiated dosing in its Ph I where TTI-621 will be evaluated as a monotherapy in patients with relapsed/refractory hematological malignancies. While TRIL has broadened its portfolio with the recent acquisition of... More
